{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=49", "query": { "condition": "Immunity Disorders", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 21205, "total_pages": 2121, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=50&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=48&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T16:03:21.207Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06561048", "title": "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Systemic Anaplastic Large Cell Lymphoma", "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell" ], "interventions": [ { "name": "Soquelitinib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-10-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 24, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561048" }, { "nct_id": "NCT00000855", "title": "A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "5 Days", "sex": "ALL", "summary": "1 Day to 5 Days" }, "enrollment_count": 35, "start_date": null, "completion_date": "2000-02", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000855" }, { "nct_id": "NCT01319526", "title": "Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma", "Nonneoplastic Condition" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2011-06", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2020-07-29", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319526" }, { "nct_id": "NCT01000285", "title": "EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia-Lymphoma, Adult T-Cell" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2010-09", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 6, "location_summary": "Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000285" }, { "nct_id": "NCT00002315", "title": "A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "Chickenpox" ], "interventions": [ { "name": "Netivudine", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002315" }, { "nct_id": "NCT03400176", "title": "VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "VAY736", "type": "DRUG" }, { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 39, "start_date": "2018-04-09", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • Columbus, Ohio + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03400176" }, { "nct_id": "NCT05305989", "title": "Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Graft-versus-host-disease" ], "interventions": [ { "name": "Belumosudil 200 mg QD", "type": "DRUG" }, { "name": "Belumosudil 200 mg BID", "type": "DRUG" }, { "name": "Belumosudil 400 mg QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kadmon, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2022-02-23", "completion_date": "2024-06-06", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 8, "location_summary": "Duarte, California • Stanford, California • St Louis, Missouri + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05305989" }, { "nct_id": "NCT02652091", "title": "Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Interferon beta-1b (Betaseron, BAY86-5046)", "type": "DRUG" }, { "name": "BETACONNECT device", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2016-02-05", "completion_date": "2017-09-13", "has_results": false, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 23, "location_summary": "Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02652091" }, { "nct_id": "NCT02765997", "title": "StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "Unmanipulated UCB", "type": "BIOLOGICAL" }, { "name": "SR-1 UCB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "2 Years to 35 Years" }, "enrollment_count": 0, "start_date": "2017-04", "completion_date": "2022-06", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02765997" }, { "nct_id": "NCT01076101", "title": "Autoimmunity in Sisters of Lupus Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [], "intervention_types": [], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "10 Years to 45 Years · Female only" }, "enrollment_count": 817, "start_date": "2009-02", "completion_date": "2016-12-31", "has_results": false, "last_update_posted_date": "2017-02-06", "last_synced_at": "2026-10-25T16:03:21.207Z", "location_count": 1, "location_summary": "Manhasset, New York", "locations": [ { "city": "Manhasset", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076101" } ] }